Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron dextran is an intravenous iron replacement agent composed of a complex of ferric hydroxide and dextran. It is indicated for the treatment of iron deficiency anemia in patients who cannot tolerate or have not responded to oral iron therapy. Following administration, the complex is phagocytized by the reticuloendothelial system, where the iron is dissociated from the dextran and subsequently binds to transferrin or is stored as ferritin. This process replenishes iron stores in the bone marrow, liver, and spleen, supporting erythropoiesis. It is commonly used in clinical settings involving chronic blood loss or malabsorption syndromes such as inflammatory bowel disease and post-gastric bypass.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron dextran (Columbia University).